{
    "Trade/Device Name(s)": [
        "AXINON\u00ae LDL-p Test System"
    ],
    "Submitter Information": "numares AG",
    "510(k) Number": "K210801",
    "Predicate Device Reference 510(k) Number(s)": [
        "K063841"
    ],
    "Regulatory Class": "Class I",
    "Product Code(s)": [
        "MRR"
    ],
    "Summary Letter Date": "July 19, 2023",
    "Summary Letter Received Date": "November 18, 2022",
    "Submission Date": "November 18, 2022",
    "Regulation Number(s)": [
        "21 CFR 862.1475"
    ],
    "Regulation Name(s)": [
        "Lipoprotein Test System"
    ],
    "Analyte Class(es)": [
        "chemistry"
    ],
    "Analyte(s)": [
        "LDL particle number (LDL-p)"
    ],
    "Specimen Type(s)": [
        "Serum"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "AXINON\u00ae Analyzer",
        "600 MHz NMR Spectrometer"
    ],
    "Method(s)/Technology(ies)": [
        "Nuclear magnetic resonance (NMR) spectroscopy"
    ],
    "Methodologies": [
        "Spectral deconvolution",
        "NMR spectral analysis"
    ],
    "Submission Type(s)": [
        "Test System",
        "Analyzer",
        "Calibrator",
        "Control"
    ],
    "Document Summary": "FDA 510(k) summary for AXINON\u00ae LDL-p Test System using NMR spectroscopy to quantify LDL particle number in human serum",
    "Indications for Use Summary": "Intended to measure lipoprotein particles to quantify LDL particle number (LDL-p) in human serum using NMR spectroscopy; results are used with other lipid measurements and clinical evaluation to aid management of lipoprotein disorders associated with cardiovascular disease, for professional use only",
    "fda_folder": "Clinical Chemistry"
}